>® (Wu Li You satisfied mAb) monotherapy compared with the fixed-dose combination of anti-LAG-3 antibody and Ou Diwo relatlimab ®
Daiichi Sankyo and Sanofi terminate cooperation on 2 combination vaccines
Time of Update: 2021-07-12
" In addition, the two companies also decided The development cooperation of the VB-0105 combination vaccine to prevent diphtheria, Haemophilus infection, whooping cough, polio and tetanus was terminated .
Deqi Pharmaceutical ATG-010 combined with ATG-008 has a significant synergistic effect in the treatment of triple-strike DLBCL
Time of Update: 2021-07-10
will announce ATG-010 (selinexor, XPO1 inhibitor) combined with ATG-008 at the 2021 American Society for Cancer Research (AACR) annual meeting (onatasertib, mTORC1/2 inhibitor) Preclinical data on the synergistic effect of triple-strike diffuse large B-cell
BeiGene announces the clinical data of Sitravatinib combined with Bazeran at the 2021 annual meeting of the American Association for Cancer Research
Time of Update: 2021-07-10
. All patients who have completed the trial will be enrolled in the group. We also look forward to deepening our understanding of the combination of drugs and providing patients all over the world with a new type of cancer therapy
Tianjing Bio announced the completion of the first patient's administration in the Chinese study of the combination of TJC4 and azacitidine
Time of Update: 2021-07-06
The recruitment of NHL and advanced solid tumor patients is expected to be completed in the fourth quarter of 2021, and the preliminary results of the clinical study will be announced at a follow-up academic conference .
BeiGene Announces a Phase 3 Clinical Trial of Baizean Combined with Chemotherapy as the First-line
Time of Update: 2021-07-06
with chemotherapy, compared to placebo in combination with chemotherapy as a treatment for recurrent or metastatic The Phase 3 RATIONALE 309 clinical trial of first-line therapy for patients with sexual nasopharyngeal carcinoma reached its primary
Ascent Pharma's MDM2 inhibitor APG-115 combined with pembrolizumab has good prospects
Time of Update: 2021-07-06
Among them, the Phase II clinical study of APG-115 combined with pembrolizumab in patients with unresectable/metastatic melanoma or advanced solid tumors who have failed immuno-oncology drug therapy has shown good prospects .
The clinical trial application of ASC40 combined with bevacizumab in the treatment of patients
Time of Update: 2021-07-06
announced today that after communicating with the National Medical Products Administration (NMPA), the clinical trial application of ASC40 combined with bevacizumab for the treatment of patients with recurrent glioblastoma (rGBM) has been accepted .
Jiangsu: Seize the "critical minority" and hit the "combined punch" of hazardous chemicals supervision
Time of Update: 2021-07-03
Table" for Hazardous Chemicals > Jiangsu is a major chemical province with a large number of chemical production, operation and storage
Corning Jerry KN046 combined with chemotherapy in the treatment of non-small cell lung cancer phase
Time of Update: 2021-07-02
combined with platinum-containing chemotherapy in patients with advanced squamous non-small cell lung cancer" (Research Number: ENREACH-LUNG-01) Interim Researchers' Meeting was held
Chuangsheng Group announced the completion of a new phase of clinical trials of TST001 combined with oxaliplatin and capecitabine
Time of Update: 2021-07-02
2) Monoclonal antibody, combined with oxaliplatin and capecitabine, was administered to the first patient in a phase I clinical study of first-line locally advanced unresectable or metastatic gastric cancer .
O drug is approved as the first-line gastric cancer, what other domestic immune combination therapies are worth looking forward to?
Time of Update: 2021-07-01
>. > The results of the study show that ORR is 85%, both are PR; DCR is 100% . The median PFS was 7. 5 months, and the incidence
The combination of precise detection and full-process management further optimizes the treatment of ALK-mutated lung cancer
Time of Update: 2021-06-30
Professor Bao Zhang: NGS dynamic monitoring is of great significance to the treatment of drug-resistant patients with gene-positive NSCLC targeted therapy.
clinical results of the new crown neutralizing antibody combination are positive
Time of Update: 2021-06-30
/> These two antibodies can non-competitively bind to the two independent and non-overlapping sites of the viral spike protein (S protein) receptor binding domain (RBD), and have a synergistic effect, thereby reducing
"The world's richest doctor" Huang Xinxiang proposed a new combination strategy, IL-15 super
Time of Update: 2021-06-30
The test mainly evaluates the combination The safety and effectiveness of the therapy in patients with advanced triple-negative breast cancer (TNBC) .
